Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

Robert L. Martuza, Amy Malick, James M. Markert, Katherine L. Ruffner, Donald M. Coen

doi:10.1126/science.1851332

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

DOI Web Site 被引用文献37件

Robert L. Martuza

Molecular Neurogenetics Laboratory, Harvard Medical School, Massachusetts General Hospital-East, Charlestown, MA 02129.
Amy Malick

Molecular Neurogenetics Laboratory, Harvard Medical School, Massachusetts General Hospital-East, Charlestown, MA 02129.
James M. Markert

Molecular Neurogenetics Laboratory, Harvard Medical School, Massachusetts General Hospital-East, Charlestown, MA 02129.
Katherine L. Ruffner

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.
Donald M. Coen

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.

抄録

<jats:p> Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 ( <jats:italic>dl</jats:italic> sptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, <jats:italic>dl</jats:italic> sptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of <jats:italic>dl</jats:italic> sptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of <jats:italic>dl</jats:italic> sptk prolonged survival. Genetically engineered viruses such as <jats:italic>dl</jats:italic> sptk merit further evaluation as novel antineoplastic agents. </jats:p>